SCHEMBL4085580

SCHEMBL4085580

CCc1cc(-c2ccc(OC)cc2)ccc1C(=O)CCC(=O)OC

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERCC5 P28715 2/20 0.48
FEN1 P39748 2/20 0.48
MAPK1 P28482 1/20 0.48
HTT P42858 3/20 0.47
ALDH1A1 P00352 2/20 0.47
HSD17B1 P14061 1/20 0.44
KMT2A Q03164 2/20 0.44
LMNA P02545 2/20 0.44
MAPT P10636 1/20 0.44
HSD17B10 Q99714 1/20 0.44
KDM4E B2RXH2 2/20 0.43
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
MEN1 O00255 1/20 0.41
CYP3A4 P08684 1/20 0.41
HSP90AA1 P07900 1/20 0.41
HPGD P15428 1/20 0.41
TSHR P16473 1/20 0.41
MMP1 P03956 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4099556 0.88 HTT (0.59) ERCC5FEN1HTTALDH1A1HSD17B1
SCHEMBL4095554 0.80 HSD17B1 (0.69) ERCC5FEN1MAPK1ALDH1A1HSD17B1
SCHEMBL13111270 0.76 NPC1 (0.60) MAPK1HTTALDH1A1KMT2ALMNA
SCHEMBL13111269 0.76 RAB9A (0.60) HTTALDH1A1KMT2ALMNAMAPT
SCHEMBL4092400 0.75 HSD17B1 (0.66) HTTHSD17B1KMT2ALMNAMAPT
SCHEMBL7639642 0.75 CYP2C19 (0.55) MAPK1HTTALDH1A1HSD17B10NPC1
SCHEMBL1108994 0.73 MMP1 (0.70) MAPK1HTTALDH1A1KMT2ALMNA
SCHEMBL11580979 0.73 NPC1 (0.61) MAPK1HTTALDH1A1KMT2ALMNA
SCHEMBL13699901 0.72 ABL1 (0.48) MAPK1LMNAMAPTKDM4ENPC1
SCHEMBL28220170 0.71 NPC1 (0.49) MAPK1HTTALDH1A1KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090186900-A1 COMPOUND STERIX LIMITED (GB) 2009-07-23 US disclosed
EP-2013176-A2 DIARYL COMPOUNDS AS NON-STEROIDAL INHIBITORS OF 17-BETA HYDROXYSTEROID DEHYDROGENASE AND/OR STEROID SULPHATASE FOR THE TREATMENT OF OESTROGEN-RELATED DISEASES SUCH AS HORMONE DEPENDENT BREAST CANCER Sterix Limited (GB) 2009-01-14 EP disclosed
WO-2007096647-A2 DIARYL COMPOUNDS AS NON-STEROIDAL INHIBITORS OF 17-BETA HYDROXYSTEROID DEHYDROGENASE AND/OR STEROID SULPHATASE FOR THE TREATMENT OF OESTROGEN-RELATED DISEASES SUCH AS HORMONE DEPENDENT BREAST CANCER STERIX LIMITED (GB) 2007-08-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090186900-A1 COMPOUND HSD17B2, HSD17B11, CYP17A1 ERCC5 4024/4885FEN1 2825/4885MAPK1 3220/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.